Gastroesophageal junction cancer Clinical Trials

Recruiting gastroesophageal junction cancer studies with sites across the US, sourced from ClinicalTrials.gov and refreshed daily. Free to join — find one near you below.

Clinical trials study new ways to prevent, detect, or treat gastroesophageal junction cancer. Joining one can give you access to investigational treatments and close monitoring by a specialist research team — at no cost — while helping advance care for others. Below are recruiting gastroesophageal junction cancer studies with sites across the US; use the location tools to find ones near you.

What to expect

Screening first. The study team reviews your eligibility before anything else — there's no obligation to continue.
Informed consent. You'll get a full explanation of the study, its potential risks and benefits, and can withdraw at any time.
No cost to you. Study visits, tests, and the investigational treatment are covered; many studies reimburse travel.

Recruiting gastroesophageal junction cancer trials

Within

Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma

for Gastric Adenocarcinoma

1 site in Philadelphia

Sponsor: Abramson Cancer Center at Penn Medicine

Sex: All·Age: 18+

Code: NCT07059611·Phase 2

Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma

for ESCC

Sponsor: Sun Yat-sen University

Sex: All·Age: 18+

Code: NCT07701681·Phase 2

Conversion Therapy With Retlirafusp Alfa Plus Chemotherapy in Gastric or Gastroesophageal Junction Adenocarcinoma

for Gastric Adenocarcinoma

Sponsor: Tang-Du Hospital

Sex: All·Age: 18 - 75

Code: NCT07709767·Phase 2

Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study

for Gastric Cancer

Sponsor: Zhifeng Zhao, PhD

Sex: All·Age: 18 - 75

Code: NCT07685704·Phase 2

HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer

for Locally Advanced Gastric Cancer

Sponsor: Shanghai Changzheng Hospital

Sex: All·Age: 18 - 75

Code: NCT07621484·Phase 2

Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer.

for Gastric Adenocarcinoma

Sponsor: Ming Liu

Sex: All·Age: 18 - 75

Code: NCT07655661·Phase 2

Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer

for Gastric Cancer (GC)

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Sex: All·Age: 18 - 75

Code: NCT07689851·Phase 2

Apply to this trial

Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma

for Gastric Adenocarcinoma

Sponsor: Nanfang Hospital, Southern Medical University

Sex: All·Age: 18 - 75

Code: NCT07603349·Phase 2, Phase 3

SKB315 in Combination Therapy in Patients With Advanced or Metastatic GC/ GEJ Adenocarcinoma

for Gastroesophageal Junction Adenocarcinoma

Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Sex: All·Age: 18 - 80

Code: NCT07609667·Phase 2

Objective Sleep Characteristics and Neoadjuvant Immunotherapy Response in Gastric/GEJ Cancer

for Gastric Adenocarcinoma

Sponsor: West China Second University Hospital

Sex: All·Age: 18+

Code: NCT07662005

Emotional Distress and Pathologic Response in Locally Advanced Gastric/GEJ Adenocarcinoma

for Gastric Adenocarcinoma

Sponsor: West China Second University Hospital

Sex: All·Age: 18+

Code: NCT07662070

A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma

for Gastric Cancer (Diagnosis)

Sponsor: Huazhong University of Science and Technology

Sex: All·Age: 18 - 75

Code: NCT07502027·Phase 4

A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment

for Gastric Cancer

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Sex: All·Age: 18 - 75

Code: NCT07518147·Phase 3

Apply to this trial

IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

for CLDN18.2 Positive

Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Sex: All·Age: 18 - 75

Code: NCT07483567·Phase 2

Apply to this trial

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

for Gastric Cancer

72 sites incl. Mobile

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT07431281·Phase 3

Apply to this trial

Study of ACC-1898 in Adult Participants With Advanced Solid Tumors

for Hepatocellular Carcinoma

Sponsor: AccSalus Biosciences, Inc.

Sex: All·Age: 18+

Code: NCT07252661·Phase 1

SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure

for Gastric Cancer (GC)

Sponsor: Jingdong Zhang

Sex: All·Age: 18+

Code: NCT07311408·Phase 2

Apply to this trial

Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for Gastric Cancer at High Risk of Peritoneal Recurrence

for Clinical Stage I Gastric Cancer AJCC v8

1 site in Rochester

Sponsor: Mayo Clinic

Sex: All·Age: 18 - 80

Code: NCT07139951·Phase 2

Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma

for Gastroesophageal Junction Adenocarcinoma

Sponsor: West China Hospital

Sex: All·Age: 18+

Code: NCT07182565·Phase 1, Phase 2

Apply to this trial

TAIC FOLFOX for Locally Advanced G/GEJA

for Gastric Cancer (Diagnosis)

Sponsor: Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Sex: All·Age: 18+

Code: NCT07655024·Phase 2

Apply to this trial

To Evaluate the Efficacy of CT041 in Sequential Treatment After First-line Treatment of Advanced Gastric/Esophagogastric Junction Adenocarcinoma

for Gastroesophageal Junction Adenocarcinoma

Sponsor: Beijing GoBroad Hospital

Sex: All·Age: 18 - 75

Code: NCT07179484

Apply to this trial

The Efficacy and Safety of Iparomlimab/Tuvonralimab (Anti PD-1/CTLA-4) Combined With Albumin-bound Paclitaxel in Second-line Treatment of Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

for Gastric Cancer

Sponsor: Qingxia Li

Sex: All·Age: 18 - 75

Code: NCT07139587

A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Adenocarcinoma

for Gastric Adenocarcinoma

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Sex: All·Age: 18 - 75

Code: NCT07152405·Phase 3

Apply to this trial

Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma

for Gastroesophageal Junction Adenocarcinoma

Sponsor: West China Hospital

Sex: All·Age: 18+

Code: NCT07072351·Phase 1, Phase 2

Apply to this trial

Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma

for Advanced Gastric Cancer

Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Sex: All·Age: 18 - 75

Code: NCT07102901·Phase 2

Apply to this trial

MAIC of Fruquintinib Plus Paclitaxel Versus Ramucirumab Plus Paclitaxel in Advanced G/GEJ Adenocarcinoma

for Advanced Gastric Cancer

Sponsor: Sun Yat-sen University

Sex: All·Age: 18+

Code: NCT07144995

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

for Metastatic Gastric Adenocarcinoma

19 sites incl. Chandler

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT07043400·Phase 3

Apply to this trial

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

for Advanced/Metastatic Solid Tumors

21 sites incl. Duarte

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07090499·Phase 1

Apply to this trial

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

for Gastric Adenocarcinoma

55 sites incl. Irvine

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 18+

Code: NCT07001748·Phase 2, Phase 3

Apply to this trial

Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

for Gastric Adenocarcinoma

Sponsor: Qilu Pharmaceutical Co., Ltd.

Sex: All·Age: 18+

Code: NCT06942767·Phase 2

Real-WorlD ZolbetUximab in Patients With HER-2 Negative and CLaudin 18.2 PosItive MetastatiC AdEnocarcinoma

for Gastric Adenocarcinoma

Sponsor: European Institute of Oncology

Sex: All·Age: 18 - 100

Code: NCT07427992

Apply to this trial

Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer

for Gastric Cancer

Sponsor: Ukrainian Society of Clinical Oncology

Sex: All·Age: 18 - 80

Code: NCT06028737·Phase 2, Phase 3

Apply to this trial

Postoperative Adjuvant Therapy for CT041 Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma Patients

for Gastroesophageal Junction Adenocarcinoma

Sponsor: Peking University

Sex: All·Age: 18 - 75

Code: NCT06857786·Phase 1

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

for HER2-positive Gastric Cancer

45 sites incl. Anchorage

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06764875·Phase 3

Apply to this trial

BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.

for Advanced or Metastatic Gastric Cancer

Sponsor: Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.

Sex: All·Age: 18 - 75

Code: NCT06773312·Phase 1

Apply to this trial

A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma

for Gastric Adenocarcinoma

Sponsor: Akeso

Sex: All·Age: 18 - 75

Code: NCT06586294·Phase 1, Phase 2

Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression

for Gastric Cancer

Sponsor: Tianjin Medical University Cancer Institute and Hospital

Sex: All·Age: 18 - 75

Code: NCT06560528·Phase 2

Apply to this trial

Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer

for Gastric Cancer

Sponsor: Tianjin Medical University Cancer Institute and Hospital

Sex: All·Age: 18 - 70

Code: NCT06454435·Phase 2

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

for Metastatic Breast Cancer

26 sites incl. Cerritos

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT06324357·Phase 1, Phase 2

Apply to this trial

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

for Advanced Esophageal Squamous Cell Carcinoma

1 site in Jacksonville

Sponsor: Mayo Clinic

Sex: All·Age: 18+

Code: NCT06265285·Phase 2

Apply to this trial

Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

for Esophageal Adenocarcinoma

2 sites incl. New York

Sponsor: Weill Medical College of Cornell University

Sex: All·Age: 18+

Code: NCT06340711·Phase 2

Apply to this trial

AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer

for Gastric Adenocarcinoma

Sponsor: Harbin Medical University

Sex: All·Age: 18 - 75

Code: NCT06196697·Phase 2

Apply to this trial

DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

for Gastric Cancer

Sponsor: RemeGen Co., Ltd.

Sex: All·Age: 18 - 75

Code: NCT06221748·Phase 2, Phase 3

Apply to this trial

A Study of KK2269 in Adult Participants With Solid Tumors

for Advanced Solid Tumor

7 sites incl. Scottsdale

Sponsor: Kyowa Kirin Co., Ltd.

Sex: All·Age: 18+

Code: NCT06266299·Phase 1

Apply to this trial

Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.

for Gastric Cancer

Sponsor: RemeGen Co., Ltd.

Sex: All·Age: 18+

Code: NCT06155383·Phase 2

Apply to this trial

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

for Colorectal Neoplasms

21 sites incl. Phoenix

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All·Age: 18+

Code: NCT06131840·Phase 1

Apply to this trial

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

for Diffuse Astrocytoma, IDH-Mutant

7 sites incl. Beverly Hills

Sponsor: Neonc Technologies, Inc.

Sex: All·Age: 18+

Code: NCT06047379·Phase 1, Phase 2

Apply to this trial

A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

for Gastric Adenocarcinoma

14 sites incl. Duarte

Sponsor: Toray Industries, Inc

Sex: All·Age: 18+

Code: NCT06038578·Phase 2

Apply to this trial

XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.

for Pancreatic Adenocarcinoma Metastatic

Sponsor: Evopoint Biosciences Inc.

Sex: All·Age: 18+

Code: NCT06792435·Phase 1, Phase 2

Apply to this trial

Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer

for Gastric Adenocarcinoma

Sponsor: UNICANCER

Sex: All·Age: 18+

Code: NCT05476796·Phase 2

Apply to this trial

Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study

for Gastric Adenocarcinoma

1 site in Rochester

Sponsor: Mayo Clinic

Sex: All·Age: 18 - 80

Code: NCT05753306·Phase 2

Apply to this trial

Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer

for Adenocarcinoma

Sponsor: Fudan University

Sex: All·Age: 18 - 75

Code: NCT06121700·Phase 2

Apply to this trial

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

for Acute Lymphoblastic Leukemia

631 sites incl. Anchorage

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 40 - 75·Accepts healthy volunteers

Code: NCT05334069

Apply to this trial

Folfox+Irinotecan+Chemort In Esophageal Cancer

for Gastroesophageal Junction Adenocarcinoma

3 sites incl. Boston

Sponsor: Massachusetts General Hospital

Sex: All·Age: 18+

Code: NCT04656041·Phase 2

Apply to this trial

Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer.

for Gastric Adenocarcinoma

Sponsor: Nanfang Hospital, Southern Medical University

Sex: All·Age: 18 - 75

Code: NCT04850729

Apply to this trial

HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)

for Gastric Cancer

Sponsor: Krankenhaus Nordwest

Sex: All·Age: 18 - 75

Code: NCT04447352·Phase 3

Apply to this trial

NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

for Cervical Esophagus Adenocarcinoma

1 site in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18+

Code: NCT04615013·Phase 1

Apply to this trial

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

for Carcinoma, Non-Small Cell Lung

104 sites incl. Anchorage

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All·Age: 18+

Code: NCT04389632·Phase 1

Apply to this trial

Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies

for Pancreatic Adenocarcinoma

1 site in Chicago

Sponsor: University of Chicago

Sex: All·Age: 18+

Code: NCT04361708·Phase 1

Apply to this trial

A Multicenter Cancer Biospecimen Collection Study

for Cancer of Head and Neck

1 site in San Francisco

Sponsor: Cofactor Genomics, Inc.

Sex: All·Age: 18+

Code: NCT04510129

Apply to this trial

Gastroesophageal junction cancer clinical trials — common questions

Are gastroesophageal junction cancer clinical trials free to join?

Yes. Participating in a gastroesophageal junction cancer clinical trial is free — study-related visits, tests, and the investigational treatment are provided at no cost to you. Many studies also reimburse travel and time. You never pay to take part.

Who can join a gastroesophageal junction cancer clinical trial?

Each gastroesophageal junction cancer study sets its own eligibility criteria — typically based on age, medical history, current treatments, and overall health. Every trial listed here shows its criteria, and the study team confirms your eligibility before enrollment. You can review and apply to any that look like a fit.

How do I find a gastroesophageal junction cancer trial near me?

Use the location controls above. We'll show recruiting gastroesophageal junction cancer trials with sites near you, sorted by distance. You can widen the radius or share your exact location for the closest matches.

How many gastroesophageal junction cancer trials are recruiting right now?

We're currently tracking roughly 27 recruiting gastroesophageal junction cancer trials with US sites, sourced from ClinicalTrials.gov and refreshed daily.

Looking for a specific location? Browse trials by city and state.

Gastroesophageal junction cancer trials by city

Duarte, CA Beverly Hills, CA Boston, MA Chicago, IL Irvine, CA Jacksonville, FL Los Angeles, CA Mobile, AL San Francisco, CA

Related specialties

Oncology GI oncology